You are here

Label-free platform for applications in drug discovery

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44TR000618-02
Agency Tracking Number: R44TR000618
Amount: $1,076,985.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCATS
Solicitation Number: PA12-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
800 RESEARCH PKWY, STE 100
OKLAHOMA CITY, OK 73104-3623
United States
DUNS: 78524346
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID GOAD
 (405) 239-8600
 david.goad@sensiqtech.com
Business Contact
 LENA FLOOD
Phone: (214) 529-1687
Email: tom.jobe@sensiqtech.com
Research Institution
 Stub
Abstract

DESCRIPTION: Incremental improvements in label free screening technologies over the past decade have not produced the capability necessary to support the changing needs of drug discovery programs. Persistent artifacts related to non-specific binding, promiscuous binding, precipitation, complex binding, tubing retention, aggregation, and sub-optimally designed platforms continue to hinder progress. Substantial progress has been made in establishing methodologies that maximize the value of the data that is currently available. The proposed platform encompasses a variety of novel adaptations including a dual mode detector exploiting surface plasmon resonance (SPR), which is sensitive to changes at the surface, and bulk solution-sensitive critical angle refractometry (CAR). Taylor dispersion-based continuous titrations (OneStepTM) and stepped analyte titrations (FastStepTM) are combined with an innovative thermal gradient capability to provide a high throughput thermodynamic screening format (DH, DS, DCp) ca

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government